Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers

Journal of Clinical Pharmacology

Volumn 52, Issue 2, 2012, Pages 195-203

  Lee, Seunghwan ^a   Kim, Bo Hyung ^a   Nam, Won Seok ^a   Yoon, Seo Hyun ^a   Cho, Joo Youn ^a   Shin, Sang Goo ^a   Jang, In Jin ^a   Yu, Kyung Sang ^a  

^a Seoul National University   (South Korea)

Author keywords

CYP2C19; pharmacogenomics; pharmacokinetics; Voriconazole

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; VORICONAZOLE; ABCB1 PROTEIN, HUMAN; ANTIFUNGAL AGENT; CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; MULTIDRUG RESISTANCE PROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; BLOOD; GENETICS; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; ANTIFUNGAL AGENTS; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 CYP3A; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEINS; POLYMORPHISM, GENETIC; VORICONAZOLE; YOUNG ADULT;

EID: 84863011832     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010395510     Document Type: Article

References (26)

1. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002 ; 347: 408-415 (Pubitemid 34851833)
2. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005 ; 366: 1435-1442 (Pubitemid 41483809)
3. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet. 2006 ; 45: 649-663 (Pubitemid 43990568)
4. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002 ; 46: 2546-2553 (Pubitemid 34793462)
5. Scholz I, Oberwittler H, Riedel KD, et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol. 2009 ; 68: 906-915
6. VFEND® (voriconazole) for injection, tablets, oral suspension [package insert]. NY, NY: Pfizer Inc; 2008. http://www.pfizer.com/files/ products/uspi-vfend.pdf. Accessed April 30, 2009.
7. Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, Nichols D. The pharmacokinetics and safety of intravenous voriconazole-a novel wide-spectrum antifungal agent. Br J Clin Pharmacol. 2003 ; 56 (suppl 1). 2-9 (Pubitemid 37491727)
8. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003 ; 31: 540-547 (Pubitemid 36444162)
9. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001 ; 52: 349-355 (Pubitemid 32939439)
10. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev. 2003 ; 35 (2-3). 99-106 (Pubitemid 37048293)
11. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics. 1996 ; 6: 441-447 (Pubitemid 26380100)
12. Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit. 1998 ; 20: 243-247 (Pubitemid 28248841)
13. Chen L, Qin S, Xie J, et al. Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics. 2008 ; 9: 691-702
14. Wakiec R, Prasad R, Morschhauser J, Barchiesi F, Borowski E, Milewski S. Voriconazole and multidrug resistance in Candida albicans. Mycoses. 2007 ; 50: 109-115
15. Cheng S, Clancy CJ, Nguyen KT, Clapp W, Nguyen MH. A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole. Antimicrob Agents Chemother. 2007 ; 51: 1855-1858 (Pubitemid 46744173)
16. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007 ; 109: 1532-1535 (Pubitemid 46595688)
17. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005 ; 35: 509-513 (Pubitemid 40403355)
18. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW. Adverse reactions to voriconazole. Clin Infect Dis. 2004 ; 39: 1241-1244 (Pubitemid 40169325)
19. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008 ; 46: 201-211 (Pubitemid 351269158)
20. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006 ; 50: 1570-1572
21. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002 ; 34: 563-571 (Pubitemid 34165316)
22. Wang G, Lei HP, Li Z, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol. 2009 ; 65: 281-285
23. Weiss J, Ten Hoevel MM, Burhenne J, et al. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol. 2009 ; 49: 196-204
24. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther. 2004 ; 75: 587-588 (Pubitemid 38746611)
25. Eichelbaum M, Kroemer HK, Fromm MF. Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs. Adv Drug Deliv Rev. 1997 ; 27: 171-199 (Pubitemid 27417872)
26. Lapple F, von Richter O, Fromm MF, et al. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 ; 13: 565-575 (Pubitemid 37168057)